Overcoming therapeutic inertia: ADA perspective

Please log in or register to do it.

Good outcomes are obtained with early glycemic control, as shown by the UK Prospective Diabetes Study (UKPDS), but the legacy benefits continue ten years after the study ending, and are also present for lipid and blood pressure management. The ADA and EASD consensus report now has, for the first time, evidence-based recommendations: among them, on a blue circle on the top of the flowchart, it is recommended to “avoid clinical inertia”, and “to reassess and modify clinical treatment regularly, every 3-6 months”(1).

L’inerzia terapeutica nella gestione del diabete mellito tipo 2 durante la pandemia Covid-19
La telemedicina tra definizioni e implicazioni comunicative